Attention should be paid to the renal injury of amoxicillin in the eradication therapy of Helicobacter pylori

doi:10.3877/cma.j.issn.2095-3216.2021.05.009

Abstract

Abstract:

Amoxicillin has a strong bactericidal activity and is widely used in the treatment of Helicobacter pylori infection. The clinical manifestations of amoxicillin-related renal injury include hematuria, proteinuria, oliguria, anuria, and acute renal failure. The main mechanisms of amoxicillin-related renal injury include the activation of immune system and crystal nephropathy. The occurrence of crystal nephropathy is related to the medication dose of amoxicillin. Due to the increasing application of high-dose amoxicillin in the radical treatment of Helicobacter pylori in recent years, the incidence of amoxicillin-related acute kidney injury has also increased. Therefore, attention should be paid to the amoxicillin-related renal injury, so that the dosage and interval of medication should be determined reasonably to better eliminate Helicobacter pylori and reduce the renal side effects.

Key words: Helicobacter pylori, Amoxicillin, Renal injury, Crystal nephropathy

Qiang Ma, Gangshi Wang. Attention should be paid to the renal injury of amoxicillin in the eradication therapy of Helicobacter pylori[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2021, 10(05): 284-287.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2021.05.009

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2021/V10/I05/284

References 30

[1]	Fallone CA, Moss SF, Melfertheiner P. Reconciliation of recent Helicobacter pylori treatment guidelines in a time of increasing resistance to antibiotics [J]. Gastroenterology, 2019, 157(1): 44-53.
[2]	Huttner A, Bielicki J, Clements MN, et al. Oral amoxicillin and amoxicillin-clavulanic acid: properties, indications and usage [J]. Clin Microbiol Infect, 2020, 26(7): 871-879.
[3]	Ghim JL, Chin MC, Jung J, et al. Pharmacokinetics and pharmacodynamics of tegoprazan co-administered with amoxicillin and clarithromycin in healthy subjects [J]. J Clin Pharmacol, 2021, 61(7): 913-922.
[4]	Thomas L, Le Beller C, Trenque T, et al. Amoxicillin-induced crystal nephropathy: a nationwide French pharmacovigilance databases study [J]. Br J Clin Pharmacol, 2020, 86(11): 2256-2265.
[5]	Ferrari B, Fogazzi GB, Garigali G, et al. Acute interstitial nephritis after amoxycillin with hematuria, red blood cell casts and hematuria-induced acute tubular injury [J]. Clin Nephrol, 2013, 80(2): 156-160.
[6]	Appel GB, Garvey G, Silva F, et al. Acute interstitial nephritis due to amoxicillin therapy [J]. Nephron, 1981, 27(6): 313-315.
[7]	Garnier AS, Dellamaggiore J, Brilland B, et al. High incidence of amoxicillin-induced crystal nephropathy in patients receiving high dose of intravenous amoxicillin [J]. J Clin Med, 2020, 9(7): 2022.
[8]	Vodovar D, Thomas L, Mongardon N, et al. Dramatic increase of amoxicillin-induced crystal nephropathy found in a cohort study of French pharmacovigilance centers [J]. Antimicrob Agents Chemother, 2018, 62(3): e01630-17.
[9]	国家药品监督管理局. 药品不良反应信息通报(第47期)警惕超剂量使用注射用阿莫西林钠可能增加肾损害发生风险[EB/OL]. 2012: URL
[10]	Bright DA, Gaupp FB, Becker LJ, et al. Amoxicillin overdose with gross hematuria [J]. West J Med, 1989, 150(6): 698-699.
[11]	Jones DP, Gaber L, Nilsson GR, et al. Acute renal failure following amoxicillin overdose [J]. Clin Pediatr (Phila), 1993, 32(12): 735-739.
[12]	Belko J, Urueta G, Emre U. Amoxicillin overdose manifested by hematuria and acute renal failure [J]. Pediatr Infect Dis J, 1995, 14(10): 917-919.
[13]	Geller RJ, Chevalier RL, Spyker DA. Acute amoxicillin nephrotoxicity following an overdose [J]. J Toxicol Clin Toxicol, 1986, 24(2): 175-182.
[14]	Schellie SF, Groshong T. Acute interstitial nephritis following amoxicillin overdose [J]. Mo Med, 1999, 96(6): 209-211.
[15]	Lee SW, Choi Y, Jang K, et al. Multiple-dose pharmacokinetics and safety of amoxicillin/clavulanate in healthy elderly subjects [J]. Int J Clin Pharmacol Ther, 2020, 58(11): 634-641.
[16]	许瑞凌，吴国贤. 阿莫西林-舒巴坦致老年患者急性间质性肾炎2例[J]. 药物不良反应杂志，2010, 12(6): 440-441.
[17]	Valluri A, Hetherington L, Mcquarrie E, et al. Acute tubulointerstitial nephritis in Scotland [J]. QJM, 2015, 108(7): 527-532.
[18]	Mulay SR, Anders HJ. Crystal nephropathies: mechanisms of crystal-induced kidney injury [J]. Nat Rev Nephrol, 2017, 13(4): 226-240.
[19]	Liu Z, Xiao Y, Chen W, et al. Calcium phosphate nanoparticles primarily induce cell necrosis through lysosomal rupture: the origination of material cytotoxicity [J]. J Mater Chem B, 2014, 2(22): 3480-3489.
[20]	付亮，唐外姣，吴海雄. 超剂量用药致尿沉渣中出现阿莫西林-克拉维酸钾结晶1例[J]. 检验医学，2020, 35(1): 92-94.
[21]	张磊，许建明．幽门螺杆菌感染处理共识解读及实施意见[J]．安徽医学，2016, 37(11): 1319-1323.
[22]	Yang JC, Lin CJ, Wang HL, et al. High-dose dual therapy issuperior to standard first-line or rescue therapy forHelicobacter pyloriinfection [J]. Clin Gastroenterol Hepatol, 2015, 13(5): 895-905.
[23]	Sahara S, Sugimoto M, Ichikawa H, et al. Efficacy of reduced dosage of amoxicillin in an eradication therapy for Helicobacter pylori infection in patients on hemodialysis: a randomized controlled trial [J]. Digestion, 2018, 97(2): 163-169.
[24]	Furuta T, Shirai N, Kodaira M, et al. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori [J]. Clin Pharmacol Ther, 2007, 81(4): 521-528.
[25]	Furuta T, Sugimoto M, Yamade M, et al. Effect of dosing schemes of amoxicillin on eradication rates of Helicobacter pylori with amoxicillin-based triple therapy [J]. J ClinPharmacol, 2014, 54(3): 258-266.
[26]	Yang J, Zhang Y, Fan L, et al. Eradication efficacy of modified dual therapy compared with bismuth-containing quadruple therapy as a first-line treatment of Helicobacter pylori [J]. Am J Gastroenterol, 2019, 114(3): 437-445.
[27]	Yu L, Luo L, Long X, et al. High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line Helicobacter pylori therapy: a randomized trial [J]. Helicobacter, 2019, 24(4): e12596.
[28]	Tai WC, Liang CM, Kuo CM, et al. A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial [J]. J Antimicrob Chemother, 2019, 74(6): 1718-1724.
[29]	Seyyed Majidi M, Sanjari Pirayvatlou P, Rajabikashani M, et al. Comparison of Helicobacter pylori eradication regimens in patients with end stage renal disease [J]. Gastroenterol Hepatol Bed Bench, 2018, 11(1): 15-19.
[30]	Gaber DA, Alhawas HS, Alfadhel FA, et al. Mini-tablets versus nanoparticles for controlling the release of amoxicillin: in vitro/in vivo study [J]. Drug Des Devel Ther, 2020, 14: 5405-5418.

Please choose a citation manager

Content to export